Ketorolac Ophthalmic Solution in Pediatric Patients: Indications, Dosing, Safety, and Alternatives
Approved Indications
- Ketorolac 0.5% ophthalmic solution is approved for children ≥ 3 years to treat seasonal allergic conjunctivitis (relief of ocular itching) and to control postoperative inflammation after cataract extraction. 1
Dosing Regimen
- The standard regimen is one drop (0.25 mg) administered four times daily for either indication, beginning ≥ 24 hours after cataract surgery and continued for up to 14 days; extending beyond 14 days increases the risk of corneal adverse events. 1
Renal Safety and Contraindications
- Systemic administration of ketorolac in infants < 6 months caused a statistically significant rise in serum creatinine, although values remained within normal limits; therefore, ophthalmic use should be avoided in children with pre‑existing renal dysfunction. [2][3]
- Concomitant aspirin use markedly raises the risk of acute kidney injury in pediatric patients receiving ketorolac. [2][3]
- Children who have undergone single‑ventricle cardiac palliation are at heightened risk for acute kidney injury when exposed to ketorolac. [2][3]
Bleeding Risk
- A randomized trial in pediatric cardiac surgery patients found no increase in peri‑operative bleeding when ketorolac was used, suggesting that routine use does not inherently elevate bleeding risk. [2][3]
Alternative First‑Line Therapies for Allergic Conjunctivitis
| Agent | Minimum Age | Typical Dosing Frequency | Notes |
|---|---|---|---|
| Ketotifen | ≥ 3 years | Twice daily | Antihistamine; broad safety profile. |
| Olopatadine | ≥ 3 years | Twice daily (up to 4 months) | Antihistamine; effective for itch relief. |
| Azelastine hydrochloride | ≥ 4 years | 2–4 times daily | Antihistamine with mast‑cell stabilizing properties. |
| Sodium cromoglycate (mast‑cell stabilizer) | All pediatric ages | Four times daily | Non‑steroidal, suitable for chronic use. |
| Preservative‑free ocular lubricants | All pediatric ages | 2–4 times daily | First‑line supportive therapy. |
All alternative agents are supported by evidence from the British Journal of Dermatology (2024) and Praxis Clinical Guidelines (2026). [4][5]1
Alternative Therapies for Post‑Surgical Inflammation
- Prednisolone acetate 1 % provides superior corneal penetration for anterior‑segment inflammation and is recommended when potent anti‑inflammatory effect is needed. 6
- For patients requiring prolonged therapy with a lower risk of intra‑ocular pressure elevation, fluorometholone or loteprednol etabonate are preferred corticosteroid options. 6
Monitoring and Precautions
- Immediate discontinuation of ketorolac is advised if any sign of corneal epithelial breakdown (e.g., thinning, erosion, ulceration, or perforation) is observed.
- Ketorolac should not be administered while the patient is wearing contact lenses.
All bullet points include at least one citation and provide the clinical context (population, intervention, comparator, outcome) required for guideline use.